India Human Papillomavirus Vaccine Market By Valence (Bivalent, Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, and Others), and By Region and Competition, Forecast & Opportunit
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIndia Human Papillomavirus Vaccine Market By Valence (Bivalent, Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, and Others), and By Region and Competition, Forecast & Opportunit
human papillomavirus
Cervical cancer is the second most common cancer among women in India, accounting for approximately 14% of all female cancers
The main reason behind cervical cancer is HPV infection, which is transmitted sexually. The HPV vaccine is highly effective in preventing HPV infections that cause most cases of cervical cancer. Several initiatives have been launched in India to increase awareness about cervical cancer prevention, including the importance of the human papillomavirus vaccine. The Indian government has also announced plans to introduce the HPV vaccine into the national immunization program, which is expected to increase access to the vaccine and reduce the burden of cervical cancer in the country. the rising prevalence of cervical cancer in India is a significant driver of the demand for human papillomavirus vaccines, and efforts to increase access and awareness about the vaccine are likely to play an important role in reducing the burden of this disease in the future.
Download Free Sample ReportImprovement In Healthcare Infrastructure
Improvements in healthcare infrastructure in India are expected to have a positive impact on the human papillomavirus vaccine market in the country, as they can increase access to healthcare services, including vaccination programs. Over the past few years, the Indian government has made significant efforts to improve healthcare infrastructure in the country. This includes initiatives, such as the Ayushman Bharat scheme, which aims to provide free health insurance coverage to millions of people in India, and the National Health Mission, which aims to provide universal access to quality healthcare services across the country. Infrastructural improvement can also lead to increased awareness about cervical cancer and the importance of HPV vaccination. For example, as more women in India have access to healthcare services, they may be more likely to receive cervical cancer screenings and learn about the importance of HPV vaccination as a preventive measure.
The availability of trained medical professionals also helps the market for the human papillomavirus vaccine in India to grow. With better healthcare infrastructure, the availability of trained medical professionals also increases. These medical professionals can be trained to administer human papillomavirus vaccines and educate patients about the vaccine and cervical cancer. Besides, improvements in healthcare infrastructure can also facilitate the delivery of HPV vaccines, such as through immunization programs and outreach efforts in rural areas. This can help to increase the uptake of the vaccine. Improvements in healthcare infrastructure are expected to be a key driver behind the growth in the India human papillomavirus vaccine market during the forecast period.
Increasing Access to Human Papillomavirus Vaccines in India
Improving access to human papillomavirus (HPV) vaccines is a key focus of the Indian government's efforts to prevent and control HPV-related diseases. Some of the initiatives aimed at increasing access to human papillomavirus vaccines in India include
The Expanded National Immunization Program
Public-Private Partnerships
Mobile Vaccination Units
Awareness and Education Campaigns
International Partnerships
Growing Middle Class and Disposable Income
Recent Developments
- In 2021 Hilleman Laboratories, ajoint venture between MSD and Welcome Trust, announced a collaboration withIndian vaccine manufacturer Bharat Biotech to develop a low-cost Human Papillomavirus vaccine for globalmarkets.
- In 2019Serum Institute ofIndia (SII) entered into a collaboration with MSD to manufacture and sell the two Human Papillomavirus vaccines in low- and middle-income countries. Under the collaboration,SII will manufacture the vaccine and distribute it in more than 150 countries.
- In 2015 GlaxoSmithKline (GSK) andMSD announced a joint venture to develop and commercialize a next-generation HumanPapillomavirus vaccine. The vaccine, called V114, received regulatory approvalin India in 2021.
Market Segmentation
Market Players
| Attribute | Details |
| Base Year | 2023 |
| Historic Data | 2018 – 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024 – 2029 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2023 and 2024-2029 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Valence Disease Indication Distribution Channel Region |
| Regional Scope | North India, South India, East India, West India |
| Key Companies Profiled | GlaxoSmithKline Pharmaceuticals Limited, MSD Pharmaceuticals Private Limited, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, HLL Lifecare Limited, Panacea Biotec Limited. |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy